The medical community is not a monolithic entity, but a complex network of relationships and influences. While national scientific key opinion leaders (KOL) and high-volume prescribers are often the focus of pharma companies’ engagement strategies, they may not be the most effective channels to drive treatment and behavioral change.
Christine Aber
Assoc. Director, Thought Leader Engagement – U.S. Medical Affairs, IQVIA
Tim Weckwerth
Principal, Thought Leader Engagement Center of Excellence, IQVIA
Deryk David
Vice President, Intercept Pharmaceuticals
U.S. Medical Affairs leverages therapeutic expertise to demonstrate the value of your therapy more effectively.
